Trials / Completed
CompletedNCT03294850
Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric Surgery
Evaluation of Biomarkers to Quantify Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis at Baseline and Following Bariatric Surgery (BARI)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- AdventHealth Translational Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate imaging and other biomarkers of non-alcoholic fatty liver disease before and after bariatric surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Bariatric surgery | Subjects enrolling in the study who are undergoing bariatric surgery as part of their medical care will be studied |
| DEVICE | HepQuant SHUNT Dual Cholate Liver Diagnostic Kit | For the experimental group, the device will be used to monitor the effect of bariatric surgery on liver function. For the active comparator group, the device will be used for the assessment of baseline liver function. |
Timeline
- Start date
- 2018-07-18
- Primary completion
- 2019-11-14
- Completion
- 2020-09-11
- First posted
- 2017-09-27
- Last updated
- 2021-07-16
- Results posted
- 2021-06-14
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03294850. Inclusion in this directory is not an endorsement.